Meeting
2019 ASCO Annual Meeting
Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma.
Authors
Mitsuaki Shirahata
Saitama Medical University International Medical Center, Saitama, Japan
Mitsuaki Shirahata , Junichi Adachi , Keiichi Kobayashi , Fumiyuki Yamasaki , Kaoru Tamura , Tomonari Suzuki , Kazuhiko Mishima , Motoo Nagane , Koichi Ichimura , Ryo Nishikawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
UMIN000012172
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2050)
DOI
10.1200/JCO.2019.37.15_suppl.2050
Abstract #
2050
Poster Bd #
239
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).
First Author: Shyam Kumar Tanguturi
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2020 ASCO Virtual Scientific Program
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.
First Author: Andrew Jehyun Song